Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Clara Lewis
New Business Observer
Posted by Clara Lewis on July 1, 2019 at 7:44 pm Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) and Viking Therapeutics Inc. (NASDAQ:VKTX) compete against each other in the Biotechnology sector. We will compare them and contrast their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Madrigal Pharmaceuticals Inc.
New Business Observer
Posted by Clara Lewis on June 27, 2019 at 12:13 am We are comparing Pfenex Inc. (NYSEAMERICAN:PFNX) and CRISPR Therapeutics AG (NASDAQ:CRSP) on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfenex Inc.
New Business Observer
Posted by Clara Lewis on June 19, 2019 at 6:29 am Both Intrexon Corporation (NASDAQ:XON) and Chimerix Inc. (NASDAQ:CMRX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
New Business Observer
Posted by Clara Lewis on June 11, 2019 at 3:27 am REGENXBIO Inc. (NASDAQ:RGNX) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation of the two firms. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO Inc.
New Business Observer
Posted by Clara Lewis on June 11, 2019 at 12:59 am Atara Biotherapeutics Inc. (NASDAQ:ATRA) and Incyte Corporation (NASDAQ:INCY), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atara Biotherapeutics Inc.
New Business Observer
Posted by Clara Lewis on June 9, 2019 at 7:48 pm This is a contrast between Trevi Therapeutics Inc. (NASDAQ:TRVI) and Editas Medicine Inc. (NASDAQ:EDIT) based on their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics Inc.
New Business Observer
Posted by Clara Lewis on June 9, 2019 at 6:50 am CRISPR Therapeutics AG (NASDAQ:CRSP) and Principia Biopharma Inc. (NASDAQ:PRNB), both competing one another are Biotechnology companies. We will compare their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CRISPR Therapeutics AG 2.09M 1082.82 185.09M -3.74 0.00 Principia Biopharma Inc.
New Business Observer
Posted by Clara Lewis on June 9, 2019 at 4:13 am Both Savara Inc. (NASDAQ:SVRA) and Alkermes plc (NASDAQ:ALKS) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara Inc.
Majedie Asset Management LTD Position in Abercrombie & Fitch Co (ANF) Trimmed by $3.19 Million; Bridger Management Position in Medicines Co (MDCO) Lifted by $13.70 Million as Market Value Rose | New Business Observer
Posted by Clara Lewis on May 25, 2019 at 1:28 pm Majedie Asset Management Ltd decreased its stake in Abercrombie & Fitch Co (ANF) by 49.21% based on its latest 2018Q4 regulatory filing with the SEC. Majedie Asset Management Ltd sold 159,637 shares as the company’s stock rose 26.11% with the market.
New Business Observer
Posted by Clara Lewis on May 23, 2019 at 2:35 pm Principia Biopharma Inc. (NASDAQ:PRNB) and Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL), both competing one another are Biotechnology companies. We will compare their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Principia Biopharma Inc.
New Business Observer
Posted by Clara Lewis on May 22, 2019 at 9:52 am NewLink Genetics Corporation (NASDAQ:NLNK) and CRISPR Therapeutics AG (NASDAQ:CRSP) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.
Kezar Life Sciences Inc. (KZR) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Comparing side by side
Posted by Clara Lewis on May 19, 2019 at 4:41 pm Kezar Life Sciences Inc. (NASDAQ:KZR) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), both competing one another are Biotechnology companies. We will contrast their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kezar Life Sciences Inc. N/A 0.00 25.86M -1.05 0.00 ZIOPHARM Oncology Inc.
As Johnson & Johnson (JNJ) Valuation Declined, Shareholder Geller Family Office Services Decreased by $326,528 Its Stake; Pinnacle Associates LTD Has Cut Esperion Therapeutics Ne (ESPR) Stake by $378,675 as Stock Price Declined | EnHerald
Geller Family Office Services Llc decreased its stake in Johnson & Johnson (JNJ) by 56.8% based on its latest 2018Q4 regulatory filing with the SEC. Geller Family Office Services Llc sold 2,551 shares as the company’s stock declined 5.44% while stock markets rallied. The institutional investor held 1,940 shares of the major pharmaceuticals company at the end of 2018Q4, valued at $250,000, down from 4,491 at the end of the previous reported quarter.
Stralem & Co Has Lowered Its Celgene Com (CELG) Position; 1832 Asset Management LP Increased Mcdonalds (MCD) Holding By $30.09 Million
Posted by Clara Lewis on May 19, 2019 at 11:39 am Stralem & Co Inc decreased Celgene Corp Com (CELG) stake by 18.43% reported in 2018Q4 SEC filing. Stralem & Co Inc sold 15,790 shares as Celgene Corp Com (CELG)’s stock rose 20.79%. The Stralem & Co Inc holds 69,903 shares with $4.48 million value, down from 85,693 last quarter. Celgene Corp Com now has $67.30 billion valuation. The stock decreased 0.09% or $0.09 during the last trading session, reaching $95.42. About 3.56M shares traded.
Contrasting of Acorda Therapeutics Inc. (ACOR) and Editas Medicine Inc. (NASDAQ:EDIT)
Posted by Clara Lewis on May 16, 2019 at 1:26 am Acorda Therapeutics Inc. (NASDAQ:ACOR) and Editas Medicine Inc. (NASDAQ:EDIT) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acorda Therapeutics Inc.
Synthorx Inc. (THOR) and Esperion Therapeutics Inc. (NASDAQ:ESPR) Comparison side by side
Posted by Clara Lewis on May 16, 2019 at 2:59 am Since Synthorx Inc. (NASDAQ:THOR) and Esperion Therapeutics Inc. (NASDAQ:ESPR) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation of both companies. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synthorx Inc.
Reviewing Editas Medicine Inc. (EDIT)'s and Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)'s results
Posted by Clara Lewis on May 15, 2019 at 9:42 pm This is a contrast between Editas Medicine Inc. (NASDAQ:EDIT) and Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) based on their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Editas Medicine Inc.
Shareholder Sabby Management Upped Biogen (BIIB) Position; Evercore Partners (EVR) Stock Price Rose While Globeflex Capital LP Cut by $818,488 Its Holding | EnHerald
Globeflex Capital LP decreased its stake in Evercore Partners Inc (EVR) by 53.14% based on its latest 2018Q4 regulatory filing with the SEC. Globeflex Capital LP sold 11,528 shares as the company’s stock rose 10.44% with the market. The institutional investor held 10,166 shares of the investment managers company at the end of 2018Q4, valued at $727,000, down from 21,694 at the end of the previous reported quarter.
Reviewing ZIOPHARM Oncology Inc. (ZIOP)'s and Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)'s results
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and Ritter Pharmaceuticals Inc. (NASDAQ:RTTR), both competing one another are Biotechnology companies. We will contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZIOPHARM Oncology Inc. N/A 0.00 144.95M -0.54 0.00 Ritter Pharmaceuticals Inc.
Comparison of CRISPR Therapeutics AG (CRSP) and Array BioPharma Inc. (NASDAQ:ARRY)
Posted by Clara Lewis on May 15, 2019 at 1:02 am This is a contrast between CRISPR Therapeutics AG (NASDAQ:CRSP) and Array BioPharma Inc. (NASDAQ:ARRY) based on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Reviewing BeyondSpring Inc. (BYSI)'s and Alkermes plc (NASDAQ:ALKS)'s results
Posted by Clara Lewis on May 14, 2019 at 2:04 am We will be contrasting the differences between BeyondSpring Inc. (NASDAQ:BYSI) and Alkermes plc (NASDAQ:ALKS) as far as profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeyondSpring Inc.
CRISPR Therapeutics AG (CRSP) and aTyr Pharma Inc. (NASDAQ:LIFE) Comparing side by side
Posted by Clara Lewis on May 14, 2019 at 12:26 am This is a contrast between CRISPR Therapeutics AG (NASDAQ:CRSP) and aTyr Pharma Inc. (NASDAQ:LIFE) based on their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.
Akcea Therapeutics Inc. (AKCA) and Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) Contrasting side by side
Posted by Clara Lewis on May 13, 2019 at 8:25 pm We are comparing Akcea Therapeutics Inc. (NASDAQ:AKCA) and Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) on their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akcea Therapeutics Inc.
Clean Yield Group Trimmed Its Columbia Ppty Tr Com New (CXP) Position by $954,598; As Nektar Therapeutics (NKTR) Share Price Declined, Shareholder Frontier Capital Management Co Lowered Stake | Crypto Coins Tribune
Clean Yield Group decreased its stake in Columbia Ppty Tr Inc Com New (CXP) by 16% based on its latest 2018Q4 regulatory filing with the SEC. Clean Yield Group sold 50,242 shares as the company’s stock rose 0.93% with the market. The institutional investor held 263,693 shares of the consumer services company at the end of 2018Q4, valued at $5.10 million, down from 313,935 at the end of the previous reported quarter.
CRISPR Therapeutics AG (CRSP)'s Financial Results Comparing With Taiwan Liposome Company Ltd. (NASDAQ:TLC)
Posted by Clara Lewis on May 11, 2019 at 6:13 am Both CRISPR Therapeutics AG (NASDAQ:CRSP) and Taiwan Liposome Company Ltd. (NASDAQ:TLC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.
Reviewing Biogen Inc. (BIIB)'s and Zogenix Inc. (NASDAQ:ZGNX)'s results
Biogen Inc. (NASDAQ:BIIB) and Zogenix Inc. (NASDAQ:ZGNX) compete against each other in the Drug Manufacturers – Major sector. We will contrast them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen Inc. 13.81B 3.18 4.67B 21.72 15.07 Zogenix Inc. N/A 0.00 128.74M -2.87 0.00 Demonstrates Biogen Inc. and Zogenix Inc.
As Walmart (WMT) Stock Value Rose, Optimum Investment Advisors Increased Holding; Ferro Corp. (FOE) Holder Mutual Of America Capital Management Has Increased Its Holding | New Business Observer
Posted by Clara Lewis on May 10, 2019 at 8:43 pm Mutual Of America Capital Management Llc increased its stake in Ferro Corp. (FOE) by 7.17% based on its latest 2018Q4 regulatory filing with the SEC. Mutual Of America Capital Management Llc bought 39,079 shares as the company’s stock declined 0.41% while stock markets rallied.
Crypto Coins Tribune
Posted by Clara Lewis on May 10, 2019 at 9:09 pm As Biotechnology businesses, BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) and Intrexon Corporation (NASDAQ:XON), are affected by contrast. This especially applies to their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BiondVax Pharmaceuticals Ltd.
Crypto Coins Tribune
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Aquestive Therapeutics Inc. (NASDAQ:AQST) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ionis Pharmaceuticals Inc.
Reviewing Sangamo Therapeutics Inc. (SGMO)'s and Editas Medicine Inc. (NASDAQ:EDIT)'s results
This is a contrast between Sangamo Therapeutics Inc. (NASDAQ:SGMO) and Editas Medicine Inc. (NASDAQ:EDIT) based on their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sangamo Therapeutics Inc. 84.45M 15.42 68.33M -0.69 0.00 Editas Medicine Inc.
Reviewing Opiant Pharmaceuticals Inc. (OPNT)'s and Intellia Therapeutics Inc. (NASDAQ:NTLA)'s results
Posted by Clara Lewis on May 9, 2019 at 2:10 am Both Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) and Intellia Therapeutics Inc. (NASDAQ:NTLA) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Opiant Pharmaceuticals Inc.
Davenport & Company Has Decreased By $1.11 Million Its Sgmo (SGMO) Position; P2 Capital Partners Has Cut Aci Worldwide (ACIW) Position
Davenport & Company Llc decreased Sgmo (SGMO) stake by 59.77% reported in 2018Q4 SEC filing. Davenport & Company Llc sold 101,085 shares as Sgmo (SGMO)’s stock declined 15.42%. The Davenport & Company Llc holds 68,025 shares with $781,000 value, down from 169,110 last quarter. Sgmo now has $1.31B valuation. The stock increased 0.18% or $0.02 during the last trading session, reaching $11.34. About 359,617 shares traded. Sangamo Therapeutics, Inc.
Crypto Coins Tribune
Posted by Clara Lewis on May 8, 2019 at 11:56 am We will be comparing the differences between Rafael Holdings Inc. (NYSEAMERICAN:RFL) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) as far as institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rafael Holdings Inc.
Crypto Coins Tribune
Posted by Clara Lewis on May 7, 2019 at 2:52 pm Both Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and Five Prime Therapeutics Inc. (NASDAQ:FPRX) are each other’s competitor in the Biotechnology industry. Thus the compare of their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Paratek Pharmaceuticals Inc.
Five Prime Therapeutics Inc. (FPRX) and Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) Comparing side by side
Posted by Clara Lewis on May 7, 2019 at 1:24 pm We are comparing Five Prime Therapeutics Inc. (NASDAQ:FPRX) and Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) on their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Five Prime Therapeutics Inc.
Spark Investment Management Lifted Its Holding in Alkermes Plc (ALKS) by $2.80 Million as Shares Declined; Pnc Finl Svcs Group (PNC) Holder Berkshire Hathaway Lifted Stake | New Business Observer
Berkshire Hathaway Inc increased its stake in Pnc Finl Svcs Group Inc (PNC) by 35.74% based on its latest 2018Q4 regulatory filing with the SEC. Berkshire Hathaway Inc bought 2.18M shares as the company’s stock declined 5.87% while stock markets rallied. The hedge fund held 8.26 million shares of the finance company at the end of 2018Q4, valued at $966.03 million, up from 6.09M at the end of the previous reported quarter.
Crypto Coins Tribune
Posted by Clara Lewis on May 7, 2019 at 5:38 am Both Advaxis Inc. (NASDAQ:ADXS) and CRISPR Therapeutics AG (NASDAQ:CRSP) are each other’s competitor in the Biotechnology industry. Thus the compare of their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Advaxis Inc.
Comparing of ACADIA Pharmaceuticals Inc. (ACAD) and IMV Inc. (NASDAQ:IMV)
Posted by Clara Lewis on May 6, 2019 at 11:58 pm ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and IMV Inc. (NASDAQ:IMV) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ACADIA Pharmaceuticals Inc.
Shareholder Weiss Multi-Strategy Advisers Lifted Callon Pete (CPE) Stake; Quantbot Technologies LP Has Trimmed Incyte (INCY) Holding by $2.32 Million; Shares Rose | Crypto Coins Tribune
Weiss Multi-Strategy Advisers Llc increased its stake in Callon Pete Inc (CPE) by 313.7% based on its latest 2018Q4 regulatory filing with the SEC. Weiss Multi-Strategy Advisers Llc bought 928,550 shares as the company’s stock declined 13.17% while stock markets rallied. The hedge fund held 1.22M shares of the oil & gas production company at the end of 2018Q4, valued at $7.95 million, up from 296,000 at the end of the previous reported quarter.
Esperion Therapeutics, Inc. (ESPR) Reaches $48.37 After 8.00% Up Move; First Bancorp Has 1.1 Sentiment
First Bancorp (FBP) investors sentiment decreased to 1.1 in Q4 2018. It’s down -0.73, from 1.83 in 2018Q3. The ratio dived, as 91 active investment managers increased and started new stock positions, while 83 sold and reduced their holdings in First Bancorp. The active investment managers in our database reported: 188.97 million shares, up from 188.90 million shares in 2018Q3.
Amicus Therapeutics (FOLD) Holder Venbio Select Advisor Has Lifted Its Stake by $7.13 Million; Cadinha & Co Has Boosted Stake in Graco (GGG) as Share Value Rose | EnHerald
Venbio Select Advisor Llc increased its stake in Amicus Therapeutics Inc (FOLD) by 8.48% based on its latest 2018Q4 regulatory filing with the SEC. Venbio Select Advisor Llc bought 791,868 shares as the company’s stock rose 29.42% with the market. The institutional investor held 10.13 million shares of the health care company at the end of 2018Q4, valued at $97.00 million, up from 9.33M at the end of the previous reported quarter.
New Business Observer
Posted by Clara Lewis on May 6, 2019 at 12:17 am Since Editas Medicine Inc. (NASDAQ:EDIT) and United Therapeutics Corporation (NASDAQ:UTHR) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation of both companies. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Editas Medicine Inc.
Ionis Pharmaceuticals Inc. (IONS) and Synlogic Inc. (NASDAQ:SYBX) Comparison side by side
Posted by Clara Lewis on May 5, 2019 at 9:06 pm Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Synlogic Inc. (NASDAQ:SYBX) compete with each other in the Biotechnology sector. We will analyze and compare their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ionis Pharmaceuticals Inc. 599.67M 17.12 276.87M 0.51 137.95 Synlogic Inc.
BioMarin Pharmaceutical Inc. (BMRN) Touches $84.10 Formed H&S; The Travelers Companies, Inc. (TRV) Had 2 Analysts Last Week
BioMarin Pharmaceutical Inc. (BMRN) formed inverse H&S with $90.83 target or 8.00% above today’s $84.10 share price. BioMarin Pharmaceutical Inc. (BMRN) has $15.06 billion valuation. The stock increased 0.90% or $0.75 during the last trading session, reaching $84.1. About 804,339 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 19.92% since May 5, 2018 and is uptrending. It has outperformed by 15.55% the S&P500.
Comparison of Kodiak Sciences Inc. (KOD) and Esperion Therapeutics Inc. (NASDAQ:ESPR)
Posted by Clara Lewis on May 5, 2019 at 6:45 am Kodiak Sciences Inc. (NASDAQ:KOD) and Esperion Therapeutics Inc. (NASDAQ:ESPR) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences Inc.
Tekla Capital Management Lifted By $766,139 Its Sangamo Therapeutics (SGMO) Position; The Cooper Companies, Inc. (COO) Covered By 7 Bulls | EnHerald
Among 9 analysts covering Cooper Companies (NYSE:COO), 7 have Buy rating, 1 Sell and 1 Hold. Therefore 78% are positive. Cooper Companies had 18 analyst reports since November 12, 2018 according to SRatingsIntel. On Monday, November 12 the stock rating was maintained by Wells Fargo with “Outperform”. The company was maintained on Wednesday, March 6 by Wells Fargo. Stephens maintained The Cooper Companies, Inc. (NYSE:COO) on Wednesday, March 6 with “Buy” rating.
New Business Observer
Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) and Sangamo Therapeutics Inc. (NASDAQ:SGMO) compete with each other in the Biotechnology sector. We will analyze and contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sunesis Pharmaceuticals Inc. N/A 390.64 26.61M -0.80 0.00 Sangamo Therapeutics Inc.
Park National Lowered Cisco Systems (CSCO) Holding; Esperion Therapeutics (ESPR) Sentiment Is 1
Park National Corp decreased Cisco Systems Inc (CSCO) stake by 2.18% reported in 2018Q4 SEC filing. Park National Corp sold 21,120 shares as Cisco Systems Inc (CSCO)’s stock rose 8.18%. The Park National Corp holds 949,269 shares with $41.13M value, down from 970,389 last quarter. Cisco Systems Inc now has $241.85B valuation. It closed at $54.94 lastly. It is up 16.80% since May 4, 2018 and is uptrending. It has outperformed by 12.43% the S&P500.
Crypto Coins Tribune
Posted by Clara Lewis on May 3, 2019 at 7:42 pm Since ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and MannKind Corporation (NASDAQ:MNKD) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of both companies. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ACADIA Pharmaceuticals Inc.
Crypto Coins Tribune
This is a contrast between Cellectar Biosciences Inc. (NASDAQ:CLRB) and Esperion Therapeutics Inc. (NASDAQ:ESPR) based on their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences Inc. N/A 0.00 15.48M -8.63 0.00 Esperion Therapeutics Inc.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Clara
Contact Clara, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack